This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Navigating the open innovation paradox: an integrative framework for adopting open innovation in pharmaceutical R&D in developing countries
The Journal of Technology Transfer Open Access 18 August 2022
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Goodman, M. Nat. Rev. Drug Discov. 8, 443 (2009).
Frei, P. & Leleux, B. Nat. Biotechnol. 22, 1049–1051 (2004).
Frei, P. & Dev, K.K. Drug Discov. Today 18, 1027–1029 (2013).
Author information
Authors and Affiliations
Corresponding authors
Ethics declarations
Competing interests
P.F. is CEO of Venture Valuation, Zurich, Switzerland.
Rights and permissions
About this article
Cite this article
O'Connell, K., Frei, P. & Dev, K. The premium of a big pharma license deal. Nat Biotechnol 32, 617–619 (2014). https://doi.org/10.1038/nbt.2946
Published:
Issue Date:
DOI: https://doi.org/10.1038/nbt.2946
This article is cited by
-
A formula for drug licensing deals
Biopharma Dealmakers (2023)
-
Navigating the open innovation paradox: an integrative framework for adopting open innovation in pharmaceutical R&D in developing countries
The Journal of Technology Transfer (2023)